RxDoctor Payments Data

Ryan Jamoua, MD

Cardiovascular Disease · Kalamazoo, MINPI 1255695987

Payments from drug & device makers

$510in general payments, 2019–2025

Across 26 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$100
  • Abbott$62
  • Novartis$62
  • Pfizer$56
  • AstraZeneca$56
  • Amgen$39
  • plus $136 from 4 others

What the payments were for

  • Food & beverage$510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$510 in reported general payments places this provider in the 20th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$122,225
Medicare patients
965
Services billed
2,103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban649$647,600
XareltoRivaroxaban187$223,444
EntrestoSacubitril/Valsartan240$221,015
JardianceEmpagliflozin52$44,390
Repatha SureclickEvolocumab40$26,408
FarxigaDapagliflozin Propanediol29$21,811
MultaqDronedarone Hcl13$19,332
Metoprolol Succinate1,023$17,796
Ranolazine ErRanolazine96$10,525
Atorvastatin Calcium603$9,370
ClopidogrelClopidogrel Bisulfate387$8,853
Praluent PenAlirocumab12$7,829
Flecainide Acetate120$5,779
Rosuvastatin Calcium261$5,681
Torsemide235$3,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$647,600649 claims
Johnson & JohnsonXarelto$100$223,444187 claims
NovartisEntresto$62$221,015240 claims
AstraZenecaFarxiga$56$21,81129 claims
Sanofi-aventis U.S. LLCMultaq$34$19,33213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →